Abstract
90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab (Bexxar) are current choices for radioimmunotherapy (RIT) of patients with follicular rituximab-relapsed or refractory CD20+ follicular B-cell NHL. Bexxar is available in the United States and Canada, while Zevalin was approved for use only in Europe. The Zevalin regimen consists of rituximab ('cold', chimeric antibody) and 90Y-ibritumomab tiuxetan ('hot' antibody). In Bexxar regimen, a tositumomab (murine antibody) is used as both, the unlabelled and labelled antibody. In both cases, the therapeutic infusion of 'hot' or radiolabelled component is preceded one week earlier by an infusion of a 'cold' or unlabelled antibody. In the US, the whole-body scanning using 111In-ibritumomab following the initial rituximab infusion is required for determination of biodistribution before the therapeutic dose of Zevalin. Bexxar regimen includes three whole body scans during the week after an imaging dose of 131I-tositumomab, which are necessary for calculation of the therapeutic dose of 131I-tositumomab. For each regimen, patients with a platelet count ?150x109/L receive a full therapeutic dose, whereas patients with platelet counts >100x109/L<150x109/L receive a modified dose of radiolabelled antibody. Therapeutic dose of Zevalin is 11-15 MBq/kg (up to maximum of 1200 MBq), while the dose of Bexxar is 1.85-5.55 GBq (maximal tolerated absorbed dose for the whole body is 75cGy). If compared to alternative treatments, the radioimmunotherapy with Bexxar and Zevalin achieves longer time to progression and longer duration of response with overall response rate between 80% to almost 100%. Repeated treatment with Zevalin or Bexxar is possible. The additional subsequent conventional therapy is compatible. Radioimmunotherapy is radiation safe and well tolerated treatment with primarily transient haematological adverse events. Pregnancy and lactation are contraindications for radioimmunotherapy. Beta radiation of 90Y allows treatment on outpatient basis.
Highlights
With follicular rituximab-relapsed or refractory CD20+ follicular B-cell NHL
Patients who are considered for radioimmunotherapy with Bexxar or Zevalin should have histopathologic confirmation of NHL lymphoma with the expression of the CD20 epitope
This kind of therapy is limited to patients with follicular low-grade lymphoma who have relapsed after treatment with rituximab or who are refractory to rituximab
Summary
90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab (Bexxar) are current choices for radioimmunotherapy (RIT) of patients Arch Oncol 2010;18(1-2):. Patients who are considered for radioimmunotherapy with Bexxar or Zevalin should have histopathologic confirmation of NHL lymphoma with the expression of the CD20 epitope At present, this kind of therapy is limited to patients with follicular low-grade lymphoma who have relapsed after treatment with rituximab or who are refractory (failed to respond) to rituximab. Retrospective study done by Wieseman et al, determined the overall response rates ranging from 74% to 82% in patients treated with Zevalin They reported that 90Y ibritumomab tiuxetan produces durable long-term responses in patients with relapsed/refractory B-cell NHL. Therapeutic activity of Bexxar is determined by dosimetry to deliver 65 to 75 cGy whole-body radiation-absorbed dose, while maximum tolerated dose for Zevalin is 1200 MBq. Since I131 is both a β and a γ emitter, Bexxar treatment results in greater exposure of medical personnel and a patient’s family. Do not take a long trip (4 hours or more) sitting near others (e.g. car, train, airplane, bus)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
